J. B. Jonas, I. Kreissig and R. Degenring, “Intravitreal Triamcinolone Acetonide for Treatment of Intraocular Proliferative, Exudative, and Neovascular Diseases,” Progress in Retinal and Eye Research, Vol. 24, No. 5, 2005, pp. 587-611. doi:10.1016/j.preteyeres.2005.01.004

has been cited by the following article:

• TITLE: Complications Following Inappropriate Intravitreal Triamcinolone Acetonide Injection

  AUTHORS: Yukishige Nakaseko, Mai Kamatani, Mineo Kondo, Yukitaka Uji, Masahiko Sugimoto

  KEYWORDS: Triamcinolone Acetonide; Intravitreal Injection

  JOURNAL NAME: Open Journal of Ophthalmology, Vol.2 No.4, November 23, 2012

  ABSTRACT: Purpose: Intravitreal Triamcinolone Acetonide (IVTA) is a useful treatment option for various intraocular diseases such as Macular Edema (ME). The treatment can cause several complications, including transient elevation of intraocular pressure and cataract formation. Here, we describe an atypical complication of IVTA. Case: A 60-year-old Japanese man presented with ME associated with central retinal vein occlusion. We performed intravitreal injection of 4 mg of TA. However, the drug spread behind the posterior lens capsule and also flowed into the anterior chamber. Although the amount of TA particles behind the lens capsule decreased over time, these particles persisted for more than 2 months. Conclusion: Although IVTA is an easy and effective treatment for ME, TA is harmful when injected into inappropriate regions of the eye. Accurate IVTA injection is important for effective treatment.